Skip to main navigation Skip to search Skip to main content

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

  • Roger Li
  • , Paras H. Shah
  • , Tyler F. Stewart
  • , Jong Kil Nam
  • , Trinity J. Bivalacqua
  • , Donald L. Lamm
  • , Edward M. Uchio
  • , Daniel M. Geynisman
  • , Joseph M. Jacob
  • , Joshua J. Meeks
  • , Rian Dickstein
  • , Shane M. Pearce
  • , Seok Ho Kang
  • , Seung Il Jung
  • , Ashish M. Kamat
  • , James M. Burke
  • , Kirk A. Keegan
  • , Gary D. Steinberg
  • Moffitt Cancer Center
  • Mayo Clinic
  • University of California at San Diego
  • Pusan National University
  • University of Pennsylvania
  • BCG Oncology
  • University of California at Irvine
  • Upstate
  • Northwestern University
  • Chesapeake Urology
  • Spokane Urology
  • Korea University
  • Chonnam National University
  • University of Texas MD Anderson Cancer Center
  • Billings Clinic
  • CG Oncology
  • Vanderbilt University
  • Rush University

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology